A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
AUTOR(ES)
Nadler, L M
RESUMO
A monoclonal antibody (anti-B1) specific for a unique B cell surface differentiation antigen was used to characterize the malignant cells from patients with leukemias or lymphomas. All tumor cells from patients with lymphomas or chronic lymphocytic leukemias, bearing either monoclonal kappa lambda light chain, expressed the B1 antigen. In contrast, tumor cells from T cell leukemias and lymphomas or acute myeloblastic leukemia were unreactive. Approximately 50% of acute lymphoblastic leukemias (ALL) of non-T origin and 50% of chronic myelocytic leukemia in blast crisis were also anti-B1 reactive. moreover, 21 of 28 patients with the common ALL antigen (CALLA) positive form of ALL were anti-B1 positive, whereas 0 of 13 patients with CALLA negative ALL were reactive. These observations demonstrate that an antigen present on normal B cells is expressed on the vast majority of B cell lymphomas and on approximately 75% of CALLA positive ALL, suggesting that these tumors may share a common B cell lineage.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=371580Documentos Relacionados
- Anti-DNA autoantibody-producing hybridomas of normal human lymphoid cell origin.
- Circular Epstein-Barr virus genomes of reduced size in a human lymphoid cell line of infectious mononucleosis origin.
- A method of identifying and isolating a unique member of a multigene family: application to a trypanosome surface antigen gene.
- Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity.
- Glycoproteins of natural origin with an affinity for hepatitis B surface antigen.